Boji Medical Technology(300404.SZ): "TBA tablets" drug clinical trials approved.

Boji Medical Technology (300404.SZ) announcement: The company has collaborated with Guangdong Gumaide Health Technology Co., Ltd. to develop and jointly apply for approval for the "TBA tablets," which has been approved by the National Medical Products Administration, with the issuance of the "Drug Clinical Trial Approval Notice." TBA is a new, structurally defined compound with pharmacological effects and clinical value. It is a class 1 innovative drug that has not been launched domestically or internationally, and its proposed indication is drug-resistant pulmonary tuberculosis.